Spencer Knight’s Post

How cost effective is CAR-T therapy? As an industry, we are seeing more analysis being done to evaluate the benefits of CAR-T therapies. One such published in the American Society of Hematology Blood Advances aimed to determine the economic viability of liso-cel for relapsed or refractory diffuse large B-cell lymphoma, compared to standard care. The data from the University of Southern California reports that: 🔎 Second-line liso-cel is cost-effective from healthcare and societal perspectives, at $100,000 per QALY gained 🔎 Productivity losses are important in order to capture broader societal values of novel therapies 🔎 CAR-T cell therapies have potential to maintain their value over time As we anticipate many more cell and gene therapy approvals this year, cost effectiveness analyses are crucial to ensure that therapies are not only approvable but accessible and affordable too. Read more ⬇️ https://lnkd.in/eGF3hSnD #manufacturingbrighterfutures #celltherapy #genetherapy #biotechnology #advancedtherapies

Nanoparticle- A promising solution to many ailments

Let's start a daily challenge to celebrate advances and good news in the cell and gene therapy space! 🎯 Aim: 1 post a day to celebrate new scientific advances, partnerships, investments, etc in cell and gene therapies and spread some positivity :) Day 1: Astellas Pharma and Poseida Therapeutics, Inc. enter into research collaboration and license agreement to develop off-the-shelf CAR-Ts for solid tumors. Combining Poseida's allogeneic technology and Xyphos' novel convertibleCAR™ approach, the collaboration aims to create flexible off-the-shelf cell therapies that can be "engineered and re-engineered inside the body to target more than one tumor antigen". Congratulations! #CGT #allogeneic #celltherapies #celebrate #monthofCGTcelebrations

#biologyfacts Nanoparticles are pivotal in medicine, notably in drug delivery, imaging, diagnostics, and therapy. They optimize drug efficacy while minimizing side effects by precisely targeting specific tissues or cells. In cancer treatment, nanoparticles transport chemotherapy drugs and aid in imaging-guided therapy as contrast agents. They also enhance imaging sensitivity and precision across various techniques. Moreover, nanoparticles facilitate sensitive diagnostic assays and can serve as theranostic agents for combined therapy and monitoring. In gene therapy, they deliver nucleic acids for targeted gene editing or expression. Overall, nanoparticles hold immense promise for advancing personalized medicine and enhancing treatment outcomes. #Nanoparticles #medicine #drugdelivery #genetherapy #cancertreatment Image from cbeh_x

To realize the full potential of Cell & Gene Therapies for treating diseases such as #Cancer or #Hemophilia, each step needs to be extensively optimized. The Genedata Biopharma Platform streamlines research and development to enable patient selection, molecule engineering, cell modification and quality control to proceed with maximum efficiency. By promoting FAIR data, automated analyses and end-to-end data capture, the Genedata Biopharma platform enables the development of fast, cost-efficient, and scalable cell therapy processes. Find out how: https://buff.ly/45IG7lT #personalizedmedicine #celltherapy #genetherapy #AAVs #CART

Academic innovators have driven groundbreaking technologies like CRISPR, gene therapies, CAR T, and mRNA. The handoff to industry is allowing such discoveries to reach patients, but some of these transformations must overcome limitations that cap their use. At #BioCenturyGrandRounds, the Modality Groundbreaker Session will spotlight potential solutions and guide drug developers on prioritizing innovations for efficient patient treatment: ➤ The heyday of AAV engineering is here: Will it deliver? ➤ The regenerative moment: Are iPSCs poised to reshape the cell therapy toolbox? ➤ Maximizing the impact of gene editing: Incremental improvements, or leaps to newer technologies? ➤ Souping up cancer cell therapies: Is the juice worth the squeeze? Download the conference brochure to view the full agenda: https://loom.ly/TGB3Mmk Register: https://loom.ly/xUy6IGo #genetherapies #drugdevelopment #geneediting #celltherapy #biopharma

🧬 Join us for an insightful discussion into the transformative world of CRISPR/Cas technology and its role in reshaping drug discovery In our latest episode, "CRISPR/Cas: Impact on Gene Editing," we explore advancements with experts Dr. Pietro De Angeli and Dr. Maarten Guerts from Tubingen University Hospital and the Princess Maxima Center for Pediatric Oncology, respectively. “The biggest hurdle at the moment is to find ways to scale these non-viral delivery methods to clinical applications.” - Pietro De Angeli 🎙️ Don't miss this concise exploration of CRISPR's influence on gene editing and the latest breakthroughs, download now: https://bit.ly/3T7dOtc #CRISPR #drugdiscovery #geneediting #innovation

I might not have been at ASGCT this year, but I definitely know all the tea! 😉 How, you ask? Continue reading... You must have read my previous post from World Orphan and how Gene Therapy will continue to dominate headlines. Keeping up with the theme, I found some small, well-funded Gene Therapy companies attending ASGCT with preclinical studies on the way. One that stood out the most to me was Gordian Biotechnology. They recently received $60M in funding, and haven’t even entered the clinics yet. With a key focus on Cell and Gene Therapies and a recent funding of over $100 million each, Obsidian Therapeutics and Neurona Therapeutics also attended the event to talk about their cell therapy research in patients with metastatic melanoma and drug-resistant chronic focal epilepsy, respectively. If I were a CGT service provider, I would have put them at the top of my list while doing the conference prep. If you didn’t get a chance to meet them, no worries, I got you! It took me less than 2 minutes to find all this information. If you are interested in finding out how I got this information, DM or email me at [email protected], and I will help you identify companies you might have missed out on during ASGCT or plan for your next conference. #ASGCT

🆕 Nema-Health, noctuRNA Therapeutics, and Telomere Therapeutics are the three advanced therapies companies chosen to take part in the Startup Support Program 2024 by #Biocat and Alira Health. ➡ Nema-Health is a #biotech company developing new #immunotherapies to treat #cancer that naturally activate the immune system to destroy tumor cells. ➡ The spinoff of the Universitat Pompeu Fabra - Barcelona, noctuRNA Therapeutics, has built a patented #RNA drug platform to tackle some of the most untreatable diseases in the world. ➡ Telomere Therapeutics, a gene therapy company, is developing disease modifying treatments for organ #fibrosis and other syndromes. The three of them will receive 40 hours of #training and, after expert evaluation, a roadmap for #market access. Read the news: 🔗 https://tuit.cat/Tobbw

Nanoparticles are pivotal in medicine, notably in drug delivery, imaging, diagnostics, and therapy. They optimize drug efficacy while minimizing side effects by precisely targeting specific tissues or cells. In cancer treatment, nanoparticles transport chemotherapy drugs and aid in imaging-guided therapy as contrast agents. They also enhance imaging sensitivity and precision across various techniques. Moreover, nanoparticles facilitate sensitive diagnostic assays and can serve as theranostic agents for combined therapy and monitoring. In gene therapy, they deliver nucleic acids for targeted gene editing or expression. Overall, nanoparticles hold immense promise for advancing personalized medicine and enhancing treatment outcomes. #nanoparticles